StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) company profile

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$74.40+4.25 (+6.06%)

Close on Nov 13, 2026Market cap $6.59BP/E –Yield –

About CG Oncology

Biological Products, (No Diagnostic Substances), SIC 2836

CG Oncology is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing cretostimogene grenadenorepvec, an oncolytic immunotherapy designed for bladder cancer. The investigational candidate features a dual mechanism of action that eliminates cancer cells through selective replication and prompts an anti-tumor immune response. Operating in the biopharmaceutical sector, the company focuses on bladder cancer therapeutics. Its target patient populations include individuals afflicted with high-risk and intermediate-risk non-muscle invasive bladder cancer, such as patients who are BCG-unresponsive, BCG-exposed, or BCG-naïve.

The company focuses its clinical pipeline on non-muscle invasive bladder cancer across diverse disease stages, addressing potential patient populations that range up to 150,000 individuals. Operations and clinical development activities are centered in the United States. CG Oncology maintains its principal executive offices and corporate headquarters in Irvine, California.

Summary of the business section of CG Oncology's latest annual report, written by StockData.

Company profile

Company

Legal name
CG Oncology, Inc.
Headquarters
Dallas, TX
Address
3000 Pegasus Park Drive, Suite 1640 75247
Phone
(949) 409-3700
Employees
142, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Irvine, California

Stock & identifiers

Ticker
CGON
Exchange
Nasdaq
IPO date
Jan 25, 2024
Shares outstanding
89M, Aug 5, 2026
Public float
$1.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1991792
CUSIP
156944100
ISIN
US1569441009
FIGI
BBG00YHKK4Q3
Share class FIGI
BBG00YHKK4R2
EIN
37-1611499

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Arthur KuanChief Executive Officer, Director200,763
Isabel KalofonosChief Commercial Officer–
James M. DetoreChief Financial Officer–
Ambaw BelletePresident and COO–
Joshua F. PattersonSee Remarks–
Vijay KasturiChief Medical Officer1,315
Bob LapetinaSee Remarks–
Corleen M. RocheCFO2,000
Leonard E. PostDirector0
James MulayDirector0
Brian Guan-Chyun LiuDirector1,886,236
Susan E. GrafDirector–
Victor Edward Tong JrDirector–
Christina RossiDirector–
Hong Fang SongDirector7,039,077

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$11.93M$28.62M$2.33M$112$131
FY2024$11.17M$23.44M$7.54M$77$98

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Arthur Kuan
Chief Executive Officer
$690.00K–$3.45M$7.35M$414.00K$22.00K$11.93M+7%
Jim DeTore
Chief Financial Officer
$96.00K–––––$96.00K–
Ambaw Bellete
President and Chief Operating Officer
$537.94K––$3.97M$268.97K$40.88K$4.82M-8%
Vijay Kasturi
Chief Medical Officer
$502.93K––$2.84M$226.32K$30.73K$3.60M–
Joshua F. Patterson
General Counsel, Chief Compliance Officer, and Secretary
$461.52K––$1.67M$207.69K$24.61K$2.36M–
Corleen Roche
Prior Chief Financial Officer
$288.89K––$2.00M–$28.73K$2.32M-76%
Robert Lapetina
Prior Interim Principal Financial and Accounting Officer
$310.22K$2.25K–$300.70K–$32.12K$645.30K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 25, 2024
Offer price
$19.00
Securities offered
20,000,000
Gross proceeds
$380.00M
Exchange
Nasdaq
First trading day
Jan 25, 2024
First-day close
$37.17+95.6%
Lock-up ends (est.)
Jul 23, 2024

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 142 employees, all of whom were full-time, 85 of whom were engaged in research and development activities and 22 of whom were engaged in commercial readiness activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?